Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

Senores Pharmaceuticals Sees Strong Q2 FY27 With 25% Revenue Jump, EBITDA Climbing 38% Amidst Portfolio Expansion

Mumbai: Senores Pharmaceuticals Limited on Wednesday, 29 October 2026, reported its unaudited financial results for the quarter and half year ended 30 September 2026. The company's revenue for the second quarter of fiscal year 2027 grew by 25% year-on-year to ₹192 crore. Profitability Growth Earnings Before Interest, Taxes, Depreciation, and Amortisation (EBITDA) for Q2 FY27 increased by 38%…

Senores Pharmaceuticals Sees Strong Q2 FY27 With 25% Revenue Jump, EBITDA Climbing 38% Amidst Portfolio Expansion

We haven't written up this one. Free Press Journal has the full story — the link below goes straight to it.

Read the original at freepressjournal.in →

More in Finance & Markets

More from Thursday 29 October →